MHRA no longer RMS from July 2018
BREAKING: MHRA will no longer to act as RMS in new EU procedures from July 2018. UK separation strategies begin.
The Medicine and Healthcare Products Regulatory Agency will no longer act as RMS in new EU procedures.
The MHRA’s official position in written correspondence remains open to interpretation and essentially pro-European.
Verbal communications with the agency confirm that the MHRA will no longer act as RMS and is unwilling to accept applications on this basis.
The principle reasons:
- The draft EU-UK withdrawal agreement expected to be ratified in October will only allow UK as a CMS.
- The Current CMDh position does not allow RMS transfer mid-procedure.
Diamond Pharma Services official position and press release due shortly.